I. Tietzova (Praha, Czech Republic), G. Hardavella (Athens, Greece)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
LSC - 2021 - Mapping of Kras mutations during chemical carcinogenesis
B. Sabine, M. Spella (magsp@upatras.gr / Department of Physiology, F. of Medicine, U. of Patras,Rio), M. A. A. Pepe (mario.pepe@helmholtz-muenchen.de / Comprehensive Pneumology Center, H. Zentrum,Munich), G. A. Giotopoulou (georgia.giotopoulou@helmholtz-muenchen.de / Comprehensive Pneumology Center, H. Zentrum,Munich), M. Lianou (lianou@upatras.gr / Department of Physiology, F. of Medicine, U. of Patras,Rio), I. Giopanou (giopanou@upatras.gr / Department of Physiology, F. of Medicine, U. of Patras,Rio), A. Lamort (anne-sophie.lamort@helmholtz-muenchen.de / Comprehensive Pneumology Center, H. Zentrum,Munich), G. T. Stathopoulos (stathopoulos@helmholtz-muenchen.de / Comprehensive Pneumology Center, H. Zentrum,Munich)
|   |
cAMP response element-binding protein mediates immune-evasion of KRAS-mutant lung adenocarcinoma
G. Giotopoulou (Munich, Germany), G. Ntaliarda (Patras, Greece), A. ?arazioti (Patras, Greece), I. Lilis (Patras, Greece), N. Spiropoulou (Patras, Greece), F. Kalogianni (Patras, Greece), E. Tourkochristou (Patras, Greece), I. Giopanou (Patras, Greece), M. Spella (Patras, Greece), M. Iliopoulou (Patras, Greece), A. Korfiati (Hampshire, United Kingdom), K. Theofilatos (Hampshire, United Kingdom), S. Mavroudi (Hampshire, United Kingdom), T. Mantamadiotis (Melbourne, Australia), T. Goldmann (Borstel, Germany), S. Marwitz (Borstel, Germany), G. Stathopoulos (Munich, Germany)
| |
PARP activity and expression in response to DNA damage in mice with lung cancer-induced cachexia
J. TANG (Barcelona, Spain), X. Wang (Barcelona, Spain), L. Qin (Barcelona, Spain), C. Ampurdanés (Barcelona, Spain), X. Duran (Barcelona, Spain), L. Pijuan (Barcelona, Spain), J. Yélamos (Barcelona, Spain), E. Barreiro (Barcelona, Spain)
| |
Lipid-related anti-cancer drug resistance of lung adenocarcinoma cells
A. Gründing (Hannover, Germany), B. Martinez-Delgado (Madrid, Spain), B. Liu (Hannover, Germany), D. Deluca (Hannover, Germany), S. Wrenger (Hannover, Germany), T. Welte (Hannover, Germany), S. Janciauskiene (Hannover, Germany)
| |
IGF1R facilitates implantation and progression of lung metastasis acting in the tumor microenvironment
E. Alfaro Arnedo (Logroño, Spain), I. López (Logroño, Spain), S. Piñeiro-Hermida (Madrid, Spain), M. Canalejo (Logroño, Spain), C. Ruíz-Martinez (Logroño, Spain), J. Pichel (Logroño, Spain)
| |
The inhibition of caspase-11 could prevent lung cancer in smoking mice
C. Colarusso (Fisciano (SA), Italy), M. Terlizzi (Fisciano (SA), Italy), A. Pinto (Fisciano (SA), Italy), R. Sorrentino (Fisciano (SA), Italy)
| |
LSC - 2021 - Macrophages in lung adenocarcinoma
N. Giannoula, I. Lilis (ioannislilis@upatras.gr / Laboratory for Molecular Respiratory Carcinogenecis, D. of Physiology, F. of Medicine, U. of Patras,Rio), M. Spella (magsp@upatras.gr / Laboratory for Molecular Respiratory Carcinogenecis, D. of Physiology, F. of Medicine, U. of Patras,Rio), G. T. Stathopoulos (stathopoulos@helmholtz-muenchen.de / Comprehensive Pneumology Center (CPC) and Institute for Lung Biology and Disease (iLBD); University Hospital, L. University and Helmholtz Zentrum München, M. of the German Center for Lung Research (DZL),Munich)
| |
LSC - 2021 - Preclinical evaluation of IL-1ß inhibition against KRAS-mutant lung adenocarcinoma
S. Georgios, G. Ntaliarda (ntaliarda@upatras.gr / Laboratory for Molecular Respiratory Carcinogenesis, D. of Physiology, F. of Medicine, U. of Patras,Rio), M. Spella (magsp@upatras.gr / Laboratory for Molecular Respiratory Carcinogenesis, D. of Physiology, F. of Medicine, U. of Patras,Rio), M. De Chateau (dechateau@buzzardpharma.com / Buzzard Pharmaceuticals, K. Institute Science Park,Stockcholm ), G. Stathopoulos (stathopoulos@helmholtz-muenchen.de / Comprehensive Pneumology Center (CPC) and Institute for Lung Biology and Disease (iLBD), U. Hospital, L. University and Helmholtz Zentrum München, M. of the German Center for Lung Research (DZL),Munich)
| |
Does acute phase protein alpha1-antitrypsin modulate apoptosis-autophagy crosstalk resulting in resistance of NSCLC cells to cancer drugs?
S. Wrenger (Hannover, Germany), A. Gründing (Hannover, Germany), T. Welte (Hannover, Germany), S. Janciauskiene (Hannover, Germany)
| |
Lung Cancer Stem Cells From Lymph Nodes Aspirates Express Immunosuppressive Molecules
A. Raniszewska (Warsaw, Poland), I. Kwiecien (Warsaw, Poland), E. Rutkowska (Warsaw, Poland), R. Sokolowski (Warsaw, Poland), J. Domagala-Kulawik (Warsaw, Poland)
| |
FGFR1 gene aberrations and FGFR1 protein expression in squamous non-small cell lung cancer (Sq-NSCLC).
J. Moes-Sosnowska (Warsaw, Poland), A. Rozy (Warsaw, Poland), M. Skupinska (Kielpin/Lomianki, Poland), U. Lechowicz (Warsaw , Poland), E. Szczepulska-Wojcik (Warsaw , Poland), R. Langfort (Warsaw , Poland), P. Rudzinski (Warsaw , Poland), T. Orlowski (Warsaw , Poland), D. Popiel (Kielpin/Lomianki, Poland), M. Wieczorek (Kielpin/Lomianki, Poland), A. Stanczak (Kielpin/Lomianki, Poland), J. Chorostowska-Wynimko (Warsaw, Poland)
| |
Regulation of PA200 in lung cancer
A. Yazgili (München, Germany), V. Welk (München, Germany), T. Meul (München, Germany), C. Lukas (München, Germany), I. Koch (Gauting, Germany), E. Stacher-Priehse (Gauting, Germany), M. Lindner (Gauting, Germany), G. Stathopoulos (München, Germany), S. Meiners (München, Germany)
| |
Microbial analysis in lung cancer according to PD-L1 level and immunotherapy response
H. Jang (Seoul, Republic of Korea), S. Yong (Seoul, Republic of Korea), E. Kim (Seoul, Republic of Korea), J. Jung (Seoul, Republic of Korea), Y. Kang (Seoul, Republic of Korea), M. Park (Seoul, Republic of Korea), Y. Kim (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), Y. Cho (Seoul, Republic of Korea)
| |
Evaluation expression of miR-146a and miR-155 and inflammatory cytokines in blood of non-small cell lung cancer patients
N. K.Dezfuli (Tehran, Islamic Republic of Iran), S. Alipoor (Tehran, Islamic Republic of Iran), N. Roofchayee (Tehran, Islamic Republic of Iran), S. Seyfi (Tehran, Islamic Republic of Iran), E. Mortaz (Tehran, Islamic Republic of Iran)
| |
High fold-changes in peripheral blood PD-1+ CD8+ T cells expressing Granzyme B predicts the response to immunotherapy in NSCLC
Y. Kim (Yangsan , Republic of Korea), J. Chung (Yangsan, Republic of Korea), S. Yoon (Yangsan, Republic of Korea), H. Seol (Yangsan, Republic of Korea)
| |
Identifying a tissue specific microRNA molecular signature in lung cancer
A. Tent (Cluj-Napoca, Romania), I. Berindan-Neagoe (Cluj-Napoca, Romania), I. Simon (Cluj-Napoca, Romania), M. Simon (Cluj-Napoca, Romania)
| |
Lung cancer biomarkers based on miRNA
M. Arroyo Varela (Málaga, Spain), E. Espinosa García (Málaga, Spain), E. Salcedo Lobera (Málaga, Spain), R. Larrosa Jiménez (Málaga, Spain), R. Bautista Moreno (Málaga, Spain)
| |
LSC - 2021 - Regulation of PA200 in lung cancer
Y. Ayse Seda, V. Welk (vanessa.welk@googlemail.com / Comprehensive Pneumology Center (CPC), U. Hospital of the Ludwig-Maximilians-University (LMU) and Helmholtz Zentrum München, M. of the German Center for Lung Research (DZL), M. Platz 31, 8. , T. Meul (thomas.meul@helmholtz-muenchen.de / Comprehensive Pneumology Center (CPC), U. Hospital of the Ludwig-Maximilians-University (LMU) and Helmholtz Zentrum München, M. of the German Center for Lung Research (DZL), M. Platz 31, 8. , C. Lukas (tina_lukas@web.de / Comprehensive Pneumology Center (CPC), U. Hospital of the Ludwig-Maximilians-University (LMU) and Helmholtz Zentrum München, M. of the German Center for Lung Research (DZL), M. Platz 31, 8. , I. Koch (ina.koch@asklepios.com / Asklepios Lung Clinic Munich-Gauting, 8. , E. Stacher-Priehse (e.stacher@asklepios.com / Asklepios Lung Clinic Munich-Gauting, 8. , M. Lindner (michael.lindner@helmholtz-muenchen.de / Asklepios Lung Clinic Munich-Gauting, 8. , G. Stathopoulos (georgios.stathopoulos@helmholtz-muenchen.de / Comprehensive Pneumology Center (CPC), U. Hospital of the Ludwig-Maximilians-University (LMU) and Helmholtz Zentrum München, M. of the German Center for Lung Research (DZL), M. Platz 31, 8. , S. Meiners (silke.meiners@helmholtz-muenchen.de / Comprehensive Pneumology Center (CPC), U. Hospital of the Ludwig-Maximilians-University (LMU) and Helmholtz Zentrum München, M. of the German Center for Lung Research (DZL), M. Platz 31, 8.
| |
Efficiency of carbon nano tube (CNT) capture of blood circulating lung cancer cells
R. Yung (Owings Mills, United States of America), S. Loeian (Coljumbus, United States of America), J. Moja (Springfieldo Alto, United States of America), R. Mehta (Muncie, United States of America), G. Krishnan (Palo Alto, United States of America), J. Park (San Francisco, United States of America), J. Allard (Gifford, United States of America), M. Myslinski (Bethlehem, United States of America)
| |